No dose-limiting toxicities occurred during the mRNA-3927 therapy in participants with propionic acidaemia.
Preliminary analysis showed a 70% reduction in the risk of metabolic decompensation events with mRNA-3927 therapy.
[
Collection
]
[
|
...
]